{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:14:31Z","timestamp":1783606471710,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019346","name":"Instituto Nacional de Cancerologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.leukres.2026.108265","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:40:52Z","timestamp":1781332852000},"page":"108265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-5951","authenticated-orcid":false,"given":"Humberto","family":"Martinez-Cordero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Spirko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma Karen","family":"Pellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Korin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-439X","authenticated-orcid":false,"given":"Perla R.","family":"Colunga-Pedraza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8682-8874","authenticated-orcid":false,"given":"Estefanie","family":"Osorio-Llanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-4487","authenticated-orcid":false,"given":"Cynthia","family":"Fuentes-Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Idrobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Noboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-7913","authenticated-orcid":false,"given":"Luis","family":"Villela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Von-Glasenapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla Noemi","family":"Britos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusaima","family":"Rodriguez-Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3853-2603","authenticated-orcid":false,"given":"Bryan","family":"Valcarcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Malpica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.leukres.2026.108265_bib1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2026.108265_bib2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/hupa.2002.124723","article-title":"AIDS-related non-Hodgkin\u2019s lymphomas: from pathology and molecular pathogenesis to treatment","volume":"33","author":"Carbone","year":"2002","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108265_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5045\/br.2020.55.1.49","article-title":"HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases","volume":"55","author":"Li","year":"2020","journal-title":"Blood Res."},{"issue":"1","key":"10.1016\/j.leukres.2026.108265_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ijlh.13863","article-title":"Plasmablastic lymphoma: an update","volume":"44","author":"Bailly","year":"2022","journal-title":"Int. J. Lab. Hematol."},{"issue":"19","key":"10.1016\/j.leukres.2026.108265_bib5","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2026.108265_bib6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.leukres.2026.108265_bib7","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2026.108265_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-020-0327-0","article-title":"Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients","volume":"10","author":"Witte","year":"2020","journal-title":"Blood Cancer J."},{"issue":"15","key":"10.1016\/j.leukres.2026.108265_bib9","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2026.108265_bib10","first-page":"1803","article-title":"Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Ramirez-Gamero","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108265_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-015-0163-z","article-title":"Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients","volume":"8","author":"Loghavi","year":"2015","journal-title":"J. Hematol. Oncol."},{"issue":"19","key":"10.1016\/j.leukres.2026.108265_bib12","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108265_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.2023021348","article-title":"The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma","volume":"143","author":"Di Ciaccio","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2026.108265_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma","volume":"15","author":"Castillo","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2026.108265_bib15","series-title":"Global AIDS Update 2023: The Path That Ends AIDS","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2023"},{"issue":"27","key":"10.1016\/j.leukres.2026.108265_bib16","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108265_bib17","first-page":"1125","article-title":"MYC and EBV interplay in B-cell lymphomas: implications for targeted therapies","volume":"15","author":"Arora","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.leukres.2026.108265_bib18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr. (Engl. Ed. )"},{"issue":"7","key":"10.1016\/j.leukres.2026.108265_bib19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/PAS.0000000000000234","article-title":"Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients","volume":"38","author":"Morscio","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108265_bib20","first-page":"687","article-title":"Daratumumab for relapsed\/refractory plasmablastic lymphoma: a case series","volume":"64","author":"Dittus","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2026.108265_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2017.09.020","article-title":"Bortezomib in plasmablastic lymphoma: a glimpse of hope for a hard-to-treat disease","volume":"62","author":"Guerrero-Garcia","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2026.108265_bib22","article-title":"Plasmablastic lymphoma: current knowledge and future directions","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:21:43Z","timestamp":1783603303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"alternative-id":["S0145212626001098"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108265","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108265"}}